Coexpression of activated c-met and death receptor 5 predicts better survival in colorectal carcinoma

American Journal of Pathology

Volumn 179, Issue 6, 2011, Pages 3032-3044

  Uddin, Shahab ^a   Hussain, Azhar R ^a   Ahmed, Maqbool ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; DEATH RECEPTOR 5; KI 67 ANTIGEN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MIDDLE EAST; MOUSE; NONHUMAN; ORGAN WEIGHT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; SULFONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 81255201331     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.08.007     Document Type: Article

References (47)

1. J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, and P. Rougier Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
2. K. Khamly, M. Jefford, M. Michael, and J. Zalcberg Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer Expert Opin Investig Drugs 14 2005 607 628 (Pubitemid 40895189)
3. H.I. Hurwitz, L. Fehrenbacher, J.D. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W.F. Novotny, and F. Kabbinavar Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 2005 3502 3508
4. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, and E. Van Cutsem Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
5. J.A. Meyerhardt, and R.J. Mayer Systemic therapy for colorectal cancer N Engl J Med 352 2005 476 487
6. J.P. Eder, G.F. Vande Woude, S.A. Boerner, and P.M. LoRusso Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin Cancer Res 15 2009 2207 2214
7. K. Breuhahn, T. Longerich, and P. Schirmacher Dysregulation of growth factor signaling in human hepatocellular carcinoma Oncogene 25 2006 3787 3800 (Pubitemid 43980474)
8. C. Liu, M. Park, and M.S. Tsao Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas Oncogene 7 1992 181 185
9. M.F. Di Renzo, M. Olivero, A. Giacomini, H. Porte, E. Chastre, L. Mirossay, B. Nordlinger, S. Bretti, S. Bottardi, S. Giordano, M. Plebani, C. Gespach, and P.M. Comoglio Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer Clin Cancer Res 1 1995 147 154
10. V.J. Wielenga, R. van der Voort, T.E. Taher, L. Smit, E.A. Beuling, C. van Krimpen, M. Spaargaren, and S.T. Pals Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer Am J Pathol 157 2000 1563 1573
11. K. Umeki, G. Shiota, and H. Kawasaki Clinical significance of c-met oncogene alterations in human colorectal cancer Oncology 56 1999 314 321 (Pubitemid 29240357)
12. J.G. Christensen, J. Burrows, and R. Salgia c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett 225 2005 1 26 (Pubitemid 40732764)
13. C.R. Goodwin, B. Lal, X. Zhou, S. Ho, S. Xia, A. Taeger, J. Murray, and J. Laterra Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation Cancer Res 70 2010 2932 2941
14. L.M. Knowles, L.P. Stabile, A.M. Egloff, M.E. Rothstein, S.M. Thomas, C.T. Gubish, E.C. Lerner, R.R. Seethala, S. Suzuki, K.M. Quesnelle, S. Morgan, R.L. Ferris, J.R. Grandis, and J.M. Siegfried HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer Clin Cancer Res 15 2009 3740 3750
15. A.R. Hussain, A.S. Khan, S.O. Ahmed, M. Ahmed, L.C. Platanias, K.S. Al-Kuraya, and S. Uddin Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells Cell Prolif 43 2010 170 183
16. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M.E. Greenberg Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241 (Pubitemid 27456390)
17. G.E. Voutsinas, and D.J. Stravopodis Molecular targeting and gene delivery in bladder cancer therapy J BUON 14 Suppl 1 2009 S69 S78
18. J. Kurebayashi, S. Okubo, Y. Yamamoto, M. Ikeda, K. Tanaka, T. Otsuki, and H. Sonoo Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells Cancer Chemother Pharmacol 58 2006 460 470 (Pubitemid 43999794)
19. F. Moschella, E. Proietti, I. Capone, and F. Belardelli Combination strategies for enhancing the efficacy of immunotherapy in cancer patients Ann N Y Acad Sci 1194 2010 169 178
20. S. Dan, M. Okamura, M. Seki, K. Yamazaki, H. Sugita, M. Okui, Y. Mukai, H. Nishimura, R. Asaka, K. Nomura, Y. Ishikawa, and T. Yamori Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations Cancer Res 70 2010 4982 4994
21. P.M. Wilson, M.J. Labonte, and H.J. Lenz Molecular markers in the treatment of metastatic colorectal cancer Cancer J 16 2010 262 272
22. D.C. Spierings, E.G. de Vries, E. Vellenga, F.A. van den Heuvel, J.J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong Tissue distribution of the death ligand TRAIL and its receptors J Histochem Cytochem 52 2004 821 831 (Pubitemid 38703137)
23. A. Suliman, A. Lam, R. Datta, and R.K. Srivastava Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways Oncogene 20 2001 2122 2133 (Pubitemid 32424006)
24. K. Schulze-Osthoff, D. Ferrari, M. Los, S. Wesselborg, and M.E. Peter Apoptosis signaling by death receptors Eur J Biochem 254 1998 439 459 (Pubitemid 28308094)
25. A. Ashkenazi, and V.M. Dixit Death receptors: signaling and modulation Science 281 1998 1305 1308 (Pubitemid 28406815)
26. S. Barua, R.S. Linton, J. Gamboa, I. Banerjee, M.L. Yarmush, and K. Rege Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists Cancer Lett 293 2010 240 253
27. U. Testa TRAIL/TRAIL-R in hematologic malignancies J Cell Biochem 110 2010 21 34
28. P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S.S. Amr, S.S. Sheikh, A. Ezzat, H. El-Solh, S. Uddin, and K. Al-Kuraya Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis Cancer Epidemiol Biomarkers Prev 15 2006 1708 1718 (Pubitemid 44497108)
29. S. Uddin, A.K. Siraj, M. Al-Rasheed, M. Ahmed, R. Bu, J.N. Myers, A. Al-Nuaim, S. Al-Sobhi, F. Al-Dayel, P. Bavi, A.R. Hussain, and K.S. Al-Kuraya Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers J Clin Endocrinol Metab 93 2008 4088 4097
30. S. Uddin, A.R. Hussain, M. Ahmed, F. Al-Dayel, R. Bu, P. Bavi, and K.S. Al-Kuraya Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma Lab Invest 90 2010 1346 1356
31. R.L. Camp, M. Dolled-Filhart, and D.L. Rimm X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 2004 7252 7259 (Pubitemid 39487712)
32. M.M. McCarthy, M. Sznol, K.A. DiVito, R.L. Camp, D.L. Rimm, and H.M. Kluger Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer Clin Cancer Res 11 2005 5188 5194 (Pubitemid 41003705)
33. J. Abubaker, P. Bavi, W. Al-Haqawi, M. Sultana, S. Al-Harbi, N. Al-Sanea, A. Abduljabbar, L.H. Ashari, S. Alhomoud, F. Al-Dayel, S. Uddin, and K.S. Al-Kuraya Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma J Pathol 219 2009 435 445
34. A.R. Hussain, M. Al-Rasheed, P.S. Manogaran, K.A. Al-Hussein, L.C. Platanias, K. Al Kuraya, and S. Uddin Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias Apoptosis 11 2006 245 254 (Pubitemid 43291024)
35. A.R. Hussain, N.A. Al-Jomah, A.K. Siraj, P. Manogaran, K. Al-Hussein, J. Abubaker, L.C. Platanias, K.S. Al-Kuraya, and S. Uddin Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells Cancer Res 67 2007 3888 3897 (Pubitemid 46762177)
36. S. Uddin, A.R. Hussain, A.K. Siraj, P.S. Manogaran, N.A. Al-Jomah, A. Moorji, V. Atizado, F. Al-Dayel, A. Belgaumi, H. El-Solh, A. Ezzat, P. Bavi, and K.S. Al-Kuraya Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 108 2006 4178 4186 (Pubitemid 44913290)
37. A.R. Hussain, M. Ahmed, N.A. Al-Jomah, A.S. Khan, P. Manogaran, M. Sultana, J. Abubaker, L.C. Platanias, K.S. Al-Kuraya, and S. Uddin Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines Mol Cancer Ther 7 2008 3318 3329
38. S. Uddin, A.R. Hussain, M. Ahmed, J. Abubaker, N. Al-Sanea, A. Abduljabbar, L.H. Ashari, S. Alhomoud, F. Al-Dayel, P. Bavi, and K.S. Al-Kuraya High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target Am J Gastroenterol 104 2009 1790 1801
39. S. Uddin, M. Ahmed, A. Hussain, J. Abubaker, N. Al-Sanea, A. AbdulJabbar, L.H. Ashari, S. Alhomoud, F. Al-Dayel, Z. Jehan, P. Bavi, A.K. Siraj, and K.S. Al-Kuraya Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy Am J Pathol 178 2011 537 547
40. G.A. Watson, X. Zhang, M.T. Stang, R.M. Levy, P.E. Queiroz de Oliveira, W.E. Gooding, J.G. Christensen, and S.J. Hughes Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma Neoplasia 8 2006 949 955 (Pubitemid 44706245)
41. R. Bu, S. Uddin, P. Bavi, A.R. Hussain, F. Al-Dayel, S. Ghourab, M. Ahmed, and K.S. Al-Kuraya HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma Lab Invest 91 2011 124 137
42. T. Mukohara, G. Civiello, I.J. Davis, M.L. Taffaro, J. Christensen, D.E. Fisher, B.E. Johnson, and P.A. Janne Inhibition of the met receptor in mesothelioma Clin Cancer Res 11 2005 8122 8130 (Pubitemid 41698757)
43. R. van der Voort, T.E. Taher, P.W. Derksen, M. Spaargaren, R. van der Neut, and S.T. Pals The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation Adv Cancer Res 79 2000 39 90 (Pubitemid 30228120)
44. R. van der Voort, T.E. Taher, R.M. Keehnen, L. Smit, M. Groenink, and S.T. Pals Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway J Exp Med 185 1997 2121 2131 (Pubitemid 27265996)
45. J.P. Fruehauf, and F.L. Meyskens Jr Reactive oxygen species: a breath of life or death? Clin Cancer Res 13 2007 789 794 (Pubitemid 46340350)
46. E.M. Jung, J.H. Lim, T.J. Lee, J.W. Park, K.S. Choi, and T.K. Kwon Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5) Carcinogenesis 26 2005 1905 1913 (Pubitemid 41631263)
47. S. Fan, Q. Meng, J.J. Laterra, and E.M. Rosen Scatter factor protects tumor cells against apoptosis caused by TRAIL Anticancer Drugs 21 2010 10 24